The application for marketing approval of Tilosin Hydrochloride Tablets (Hua Ke Si®) for the treatment of “excessive daytime sleepiness (EDS) or cataplexy in children and adolescents aged 6 years and above with narcolepsy” has been included in the priority review and approval process. Not long ago, the first indication of Hua Ke Si® in my country – for the treatment of “excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy” was approved.
Let us work together to protect precious health